Exact Sciences Reports Strong Growth Trajectory for Cologuard™ in First-Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Lake Street Capital Markets Downgrades Exact Sciences (EXAS) to Hold
May 5, 2015 9:22 AM EDTLake Street Capital Markets downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold with a price target of $24.00 (from $28.00). The change follows Q1 results, which were described as slightly better than expected. Analyst Bruce D. Jackson said Cologuard unit ramp and commercial pricing... More
Exact Sciences (EXAS) Tops Q1 EPS by 1c, Company Pleased with Launch Trajectory of Cologuard
May 4, 2015 8:56 AM EDTExact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.40), $0.01 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.11 million.
11,000 Cologuard tests were completed and the number of ordering physicians more than doubled,... More
